0
Translating Basic Research Into Clinical Practice |

Malignant mesothelioma biomarkers – from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment OPEN ACCESS

Jenette Creaney, PhD; Bruce W.S. Robinson, MBBS, FRACP, MD
Author and Funding Information

The authors have no conflict of interest to disclose.

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia

Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia

Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

Corresponding Author: Prof. Jenette Creaney, ; School of Medicine and Pharmacology, M503, QQ Block, Queen Elizabeth II Medical Centre, Nedlands, Perth, 6009, Australia.


Copyright 2016, . All Rights Reserved.


Chest. 2016. doi:10.1016/j.chest.2016.12.004
Text Size: A A A
Published online

Abstract

Malignant pleural mesothelioma is a highly aggressive tumour associated with asbestos exposure. There are few effective treatment options for mesothelioma and patients have a very poor prognosis with a median survival of less than 12 months from diagnosis. Biomarkers have been proposed as a cost-effective means of cancer management and the search for a mesothelioma biomarker has been on-going for the past thirty years. Many traditional soluble (glyco)-protein biomarkers have been evaluated over this time and an ever increasing list of new biomarkers, including mRNA, DNA, miRNA and antibodies, are being reported from biomarker discovery projects. To date, soluble mesothelin is the only tumour biomarker to receive FDA approval for clinical use in mesothelioma. Mesothelin is a glycoprotein normally expressed on the surface of mesothelial cells, and in the cancerous state can be present in the circulation. Mesothelin has a limited expression on normal, non-malignant tissue and is thus an attractive therapeutic target for mesothelin-positive tumours. In this review we will focus on the discovery and clinical usages of mesothelin and provide an update on other mesothelioma biomarkers and show how such biomarker studies might impact on the management of this deadly tumour in the future.


This article is only available in the PDF format. Download the PDF

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543